- Home
- PLRX vs PHAR Comparison
PLRX vs PHAR Comparison
Compare PLRX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- PHAR
- Stock Information
- Founded
- PLRX 2015
- PHAR 1988
- Country
- PLRX United States
- PHAR Netherlands
- Employees
- PLRX N/A
- PHAR N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- PHAR Health Care
- Exchange
- PLRX Nasdaq
- PHAR Nasdaq
- Market Cap
- PLRX 93.3M
- PHAR 951.7M
- IPO Year
- PLRX 2020
- PHAR N/A
- Fundamental
- Price
- PLRX $1.79
- PHAR $13.20
- Analyst Decision
- PLRX Hold
- PHAR Strong Buy
- Analyst Count
- PLRX 11
- PHAR 3
- Target Price
- PLRX $3.93
- PHAR $30.00
- AVG Volume (30 Days)
- PLRX 1.0M
- PHAR 10.6K
- Earning Date
- PLRX 11-07-2025
- PHAR 11-06-2025
- Dividend Yield
- PLRX N/A
- PHAR N/A
- EPS Growth
- PLRX N/A
- PHAR N/A
- EPS
- PLRX N/A
- PHAR N/A
- Revenue
- PLRX N/A
- PHAR $339,836,000.00
- Revenue This Year
- PLRX N/A
- PHAR $17.70
- Revenue Next Year
- PLRX N/A
- PHAR $12.25
- P/E Ratio
- PLRX N/A
- PHAR N/A
- Revenue Growth
- PLRX N/A
- PHAR 22.44
- 52 Week Low
- PLRX $1.10
- PHAR $7.31
- 52 Week High
- PLRX $16.10
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- PLRX 60.55
- PHAR 43.02
- Support Level
- PLRX $1.72
- PHAR $13.08
- Resistance Level
- PLRX $1.95
- PHAR $14.10
- Average True Range (ATR)
- PLRX 0.12
- PHAR 0.52
- MACD
- PLRX 0.03
- PHAR -0.17
- Stochastic Oscillator
- PLRX 67.00
- PHAR 6.94
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.